The AD drug development pipeline has 105 agents divided among phase I, phase II, and phase III. 2 key findings →
Participants: 54,073 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
We surveyed 1,545 subjects--recruited into the UK Medical Research Council elderly hypertension treatment trial between 1982 and 1987--to detect incident cases of dementia, identifying 50 cases of dementia, including 31 cases of probable or possible Alzheimer's disease (AD). 2 key findings →
Participants: 1,545 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In vitro and animal studies have suggested that inoculation with herpes simplex virus 1 (HSV-1) can lead to amyloid deposits, hyperphosphorylation of tau, and/or neuronal loss. 4 key findings →
Participants: 58 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The CDR-SB assesses both cognitive and functional domains of AD disability. 4 key findings →
Participants: 382 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The authors observed that “Our findings showed that nurses provided chronic disease management that was acceptable, feasible and sustainable.” 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
At baseline, there were 126 participants (106 [84.1%] women); mean (SD) age was 44.13 (12.71) years, mean years of interpreting experience was 8.57 (8.48) years, and 106 of 120 (88.3%) lived in an urban area. 5 key findings →
Participants: 126 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to evaluate the impact of a year-long, home-based individual cognitive stimulation (iCS) program on cognitive performance, mood, functional independence, and quality of life (QoL) in older adults with mild Alzheimer’s disease and vascular dementia. 2 key findings →
Design: randomized controlled trial Participants: 18 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In total, 156 individuals were assessed for eligibility, and 79 (51%) were recruited (mean age 61.6 ± 6.9 (range 60-75) years; 68% male). 5 key findings →
Participants: 156 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
=0.03), indicating improved executive function. 5 key findings →
Design: randomized controlled trial Participants: 33 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This paper examines eight published reviews that each pooled results from several related clinical trials to evaluate treatment efficacy. 4 key findings →
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cogmed was better on one core WM measure and had higher ratings of satisfaction. 5 key findings →
Participants: 68 Evidence: high
Full summary, score breakdown and related studies → Original source
Hypertension is associated with impaired cognition, and when combined with MCI, it may lead to a poor prognosis. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
This pilot study is the first trial evaluating the potential benefits of home-based tailored and adaptive CCT in relation to cognitive and disease self-management in older diabetic adults. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Percentage of visually tau-positive scans increased with amyloid-beta deposition measured in 18F-florbetaben Centiloids (CL) (7.7% (<36 CL), 80% (>83 CL)). 18F-PI-2620 standardized uptake value ratio (SUVR) was correlated with increased 18F-florbetaben CL in several regions of interest. 5 key findings →
Design: clinical trial Participants: 74 Evidence: low
Full summary, score breakdown and related studies → Original source
Conventional parallel group randomized controlled clinical trials (RCT) in Alzheimer’s disease (AD) are too large, long, expensive and insensitive to clinical change to meet the urgent need for an effective treatment. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Crenezumab is a humanized anti-amyloid-beta (Aβ) monoclonal IgG4 antibody in development for the treatment of Alzheimer’s disease (AD). 2 key findings →
Design: clinical trial Participants: 500 Evidence: high
Full summary, score breakdown and related studies → Original source
RVT-101 is a 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of dementia with a number of favorable properties including once daily dosing, lack of food effect, and low potential for drug interactions. 4 key findings →
Design: clinical trial Participants: 684 Evidence: high
Full summary, score breakdown and related studies → Original source
The efficacy of the ginkgo biloba special extract EGb 761 in outpatients with presenile and senile primary degenerative dementia of the Alzheimer type (DAT) and multi-infarct dementia (MID) according to DSM-III-R was investigated in a prospective, randomized, double-blind, placebo-controlled, multi-center study. 2 key findings →
Participants: 216 Evidence: high
Full summary, score breakdown and related studies → Original source
Among the 2446 patients who received tacrine in clinical trials, ALT levels greater than the upper limit of normal (ULN) occurred on at least one occasion in 1203 patients (49%), ALT levels greater than three times the ULN occurred in 621 patients (25%), and ALT levels greater than 20 times the ULN occurred in 40 patients (2%). 5 key findings →
Design: open-label trial Participants: 2,446 Evidence: low
Full summary, score breakdown and related studies → Original source
P‐tau181 in CSF and plasma predicted tau accumulation (r > 0.36, P < .001), even in AD‐continuum individuals with normal baseline tau‐PET (A+T–; r > 0.37, P < .05). 4 key findings →
Participants: 163 Evidence: low
Full summary, score breakdown and related studies → Original source
In total, 100 subjects completed the study. 5 key findings →
Design: clinical trial Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source
Clinical trials testing tau-targeting therapies may benefit from using fluid biomarkers to recruit individuals at risk of tau aggregation. 1 key finding →
Participants: 163 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. 5 key findings →
Participants: 445 Evidence: low
Full summary, score breakdown and related studies → Original source
Retrotransposons constitute over 40% of the human genome. 2 key findings →
Design: open-label trial Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 1,875 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Psychosis of Alzheimer disease: validity of the construct and response to risperidone
- The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement
- Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study
- Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial
- Donepezil in the treatment of patients with Alzheimer's disease
- Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial
- Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results
- Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults
- A Mediterranean diet supplemented with dairy foods improves mood and processing speed in an Australian sample: results from the MedDairy randomized controlled trial
- Communication Bridge-2 randomized controlled trial: Recruitment and baseline features
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →